Q3 EPS Forecast for Merit Medical Systems Lowered by Analyst

Merit Medical Systems, Inc. (NASDAQ:MMSI) – Stock analysts at Zacks Research dropped their Q3 2027 earnings per share estimates for shares of Merit Medical Systems in a research note issued on Friday, July 17th. Zacks Research analyst Team now forecasts that the medical instruments supplier will earn $0.97 per share for the quarter, down from their previous estimate of $0.98. The consensus estimate for Merit Medical Systems’ current full-year earnings is $3.62 per share. Zacks Research also issued estimates for Merit Medical Systems’ FY2027 earnings at $3.82 EPS and Q1 2028 earnings at $0.94 EPS.

Merit Medical Systems (NASDAQ:MMSI) last issued its earnings results on Thursday, April 30th. The medical instruments supplier reported $0.94 EPS for the quarter, beating the consensus estimate of $0.84 by $0.10. The business had revenue of $381.88 million for the quarter, compared to the consensus estimate of $377.59 million. Merit Medical Systems had a return on equity of 13.54% and a net margin of 9.03%.The company’s revenue was up 7.4% compared to the same quarter last year. During the same period last year, the business posted $0.86 EPS. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS.

MMSI has been the subject of several other reports. JPMorgan Chase & Co. reduced their price objective on Merit Medical Systems from $95.00 to $77.00 and set an “overweight” rating for the company in a report on Friday, May 1st. Barrington Research lowered their target price on shares of Merit Medical Systems from $109.00 to $107.00 and set an “outperform” rating on the stock in a research note on Monday, April 20th. Needham & Company LLC dropped their price target on shares of Merit Medical Systems from $101.00 to $90.00 and set a “buy” rating on the stock in a report on Friday, May 1st. Robert W. Baird set a $83.00 price target on shares of Merit Medical Systems in a research note on Friday, May 1st. Finally, Citigroup reissued an “outperform” rating on shares of Merit Medical Systems in a report on Monday, April 20th. Eight analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $92.80.

Merit Medical Systems Trading Down 2.2%

Shares of NASDAQ:MMSI opened at $73.48 on Tuesday. The company has a market cap of $4.38 billion, a P/E ratio of 31.81, a PEG ratio of 2.34 and a beta of 0.52. The company has a debt-to-equity ratio of 0.45, a current ratio of 5.08 and a quick ratio of 3.46. Merit Medical Systems has a 1 year low of $59.74 and a 1 year high of $94.75. The stock’s fifty day moving average price is $67.51 and its 200-day moving average price is $72.32.

Insider Buying and Selling at Merit Medical Systems

In other Merit Medical Systems news, Director Lynne N. Ward sold 5,000 shares of the stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $62.61, for a total value of $313,050.00. Following the transaction, the director owned 7,809 shares of the company’s stock, valued at approximately $488,921.49. This represents a 39.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Brian G. Lloyd bought 2,000 shares of the company’s stock in a transaction on Thursday, May 7th. The stock was purchased at an average cost of $62.62 per share, for a total transaction of $125,240.00. Following the completion of the transaction, the insider directly owned 2,000 shares of the company’s stock, valued at approximately $125,240. The trade was a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 0.70% of the company’s stock.

Institutional Investors Weigh In On Merit Medical Systems

Hedge funds and other institutional investors have recently made changes to their positions in the business. Los Angeles Capital Management LLC purchased a new position in shares of Merit Medical Systems in the fourth quarter worth approximately $25,000. Maseco LLP purchased a new stake in Merit Medical Systems during the fourth quarter valued at approximately $26,000. Torren Management LLC purchased a new stake in Merit Medical Systems during the fourth quarter valued at approximately $38,000. Covestor Ltd increased its holdings in Merit Medical Systems by 252.6% during the fourth quarter. Covestor Ltd now owns 469 shares of the medical instruments supplier’s stock valued at $41,000 after buying an additional 336 shares during the last quarter. Finally, Danske Bank A S bought a new position in Merit Medical Systems in the third quarter worth approximately $42,000. Hedge funds and other institutional investors own 99.66% of the company’s stock.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.